Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM)

Key facts

Sponsor

University Hospital, Brest

Enrollment

10 target

Eligibility

18 years · All sexes

Timeline

2024 – 2028

Study locations (1)

• Chu Brest, Brest, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07441694
  Study of INCA036978 in Participants With Myeloproliferative Neoplasms
  Incyte Corporation
• RECRUITINGPHASE2NCT07148947
  Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
  University of Washington
• RECRUITINGPHASE2NCT07228624
  Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
  Fred Hutchinson Cancer Center
• RECRUITINGNANCT07119970
  Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
  University Hospital, Bordeaux
• RECRUITINGPHASE2NCT06661915
  A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
  National Cancer Institute (NCI)
• RECRUITINGPHASE3NCT06468033
  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
  PharmaEssentia
• RECRUITINGNANCT05745285
  Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
  University of Miami
• RECRUITINGNCT06480591
  Evaluation of the Pathobiology of CALR-mutated MPN Cells
  Wake Forest University Health Sciences

See all trials for Myeloproliferative neoplasm →